Stay up to date on the latest market news with daily analysis of the investing landscape, served up Brew-style.

Brew Markets

Morning Brew

Money with Katie

Morning Brew Daily 

Bossy

Per My Last Email

After Earnings

Our Future

CFO Brew

Healthcare Brew

HR Brew

IT Brew

Marketing Brew

Retail Brew

Tech Brew

Automakers

Commodities

Cryptocurrencies

Macro Economics

Stocks

Stock Market News

Explainers

Events

brewmarkets.com

When ChatGPT first launched, Public spotted an opportunity. They asked: How could this technology potentially benefit retail investors? And thus, Alpha was born in 2023. Think of it as a chat interface and research assistant for investing FAQs. Questions like “Why is this stock moving?” or “Can you show me an earnings report?” can be given a considered response, providing background data to help make faster decisions.

In fact, in recent years of AI being available for market questions, retail investors have been doing just that. Public found that with AI, 25% of members who use Public’s Alpha make a trade within three hours of asking a question.

But speed doesn’t necessarily beget accuracy. This begs the question: Where is the balance? With AI arriving in a big way on the investing scene, where will it be used outside of research? Early use cases are showing AI can help retail investors build customized portfolios based on the themes they’re interested in.

To learn more, Brew Markets’ Ann Berry sits down with Stephen Sikes, COO of Public, to discuss what’s next for AI usage in the retail investing space. Tune in to find out.

Speakers

Questions?

AI is reshaping how retail investors research, trade, and even build personalized portfolios—but speed doesn’t always guarantee accuracy. Join Brew Markets’ Ann Berry and Public COO Stephen Sikes as they explore where AI is adding value in investing today and where it’s headed next.

Light green key on a dark green background

(Fund)amental Tech: How Retail Investors Are Embracing AI

Lucy Brewster

There are people out there giving bad investing advice—and then there are those who keep proselytizing even after being convicted of securities fraud.

Martin Shkreli, the infamous executive who made a name for himself by raising the price of a life-saving medication by 5,000%, has been touting a bunch of bets against pharmaceutical companies on X. Even stranger, his track record is actually…pretty good so far?

While Shkreli’s drug-pricing antics spurred a ton of headlines and hate for him, that incident is not what got him convicted of securities fraud. That little hiccup had to do with manipulating the stock of his pharma company Retrophin and 

Apparently, his experience at the helm of a pharmaceutical company has given him some insight into spotting fellow pharma frauds. Back in November 2024, Shkreli announced he was shorting Cassava Sciences, arguing that he doesn’t think the company’s Alzheimer’s treatment works. Its stock has fallen 24% this year.

He also shorted INmune Bio at the end of June, again noting that its hit drug “basically doesn’t work.” Shares immediately plunged 56% the next trading day, and remain down 21.34% over the last month.

More recently, at the end of July he announced he was 

. He warned that the company had “some of the worst data I've ever seen,” and said shares will fall 80% in the next four to six weeks. The stock has dropped 78% over the past month.

: None of that means you should take your investment advice from the Pharma Bro. It’s more likely that, in a world of meme stocks and internet cache, Shkreli has garnered enough of an investor following that retail traders are backing up his calls with big money, making his predictions a reality.

Then again, the former pharma exec also dropped another piece of news today on X: He’s shorting 

. Shkreli isn’t the only one worried about OpenDoor’s valuation—for once, the majority of analysts 

Pharma Bro declares pharma no-no

Shkreli’s short-selling stats

Making sense of market moves